Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 2/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674382 | 0.91 | ALDH1A1 (0.34) | GBA1UGCGGBA2ALDH1A1ADRB1 | |
| SCHEMBL127677 | 0.91 | ALDH1A1 (0.34) | GBA1UGCGGBA2ALDH1A1ADRB1 | |
| SCHEMBL131694 | 0.89 | GBA1 (0.38) | GBA1UGCGGBA2ADRB1LMNA | |
| SCHEMBL13954701 | 0.84 | GBA1 (0.33) | GBA1UGCGGBA2 | |
| SCHEMBL16674491 | 0.83 | HSD17B10 (0.34) | ALDH1A1ADRB1LMNACYP2D6MEN1 | |
| SCHEMBL9426350 | 0.82 | SGPL1 (0.30) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL131809 | 0.80 | GBA1 (0.33) | GBA1UGCGGBA2ALDH1A1ADRB1 | |
| SCHEMBL131722 | 0.77 | SLC1A3 (0.32) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL29117245 | 0.76 | SLC1A3 (0.37) | GBA1UGCGGBA2 | |
| SCHEMBL18537061 | 0.75 | CYP1A2 (0.39) | CYP1A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | GBA1 1194/4885UGCG 1855/4885GBA2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.